Number of AEs and SAEs
| . | Canakinumab . | Placebo . |
|---|---|---|
| Number of AEs occurring in the number of patients | 101 in 21 | 150 in 23 |
| AE severity grade | ||
| Mild | 68 in 17 | 86 in 18 |
| Moderate | 26 in 15 | 55 in 19 |
| Severe | 7 in 4 | 9 in 3 |
| Study drug–related AEs | 4 in 3 | 4 in 3 |
| SAEs | 19 in 11 | 42 in 15 |
| . | Canakinumab . | Placebo . |
|---|---|---|
| Number of AEs occurring in the number of patients | 101 in 21 | 150 in 23 |
| AE severity grade | ||
| Mild | 68 in 17 | 86 in 18 |
| Moderate | 26 in 15 | 55 in 19 |
| Severe | 7 in 4 | 9 in 3 |
| Study drug–related AEs | 4 in 3 | 4 in 3 |
| SAEs | 19 in 11 | 42 in 15 |